Cancer in common variable immune deficiency
| Type . | NY3 (N = 473), % (n) . | USIDNET23 (N = 1285), % (n) . | ESID2 (N = 2700), % (n) . | Italian21 (N = 455), % (n) . | Czech22 (N = 295), % (n) . |
|---|---|---|---|---|---|
| Any neoplasm | 14.4% (68) | 9.2% (119) | — | 29% (133) | 7.4% (25) |
| Non-Hodgkin lymphoma | 7.0% (33) | 2.2% (37) | 3.8% (103) | 7.2% (33) | 1.3% (4) |
| Solid tumors | — | — | 5.5% (149) | — | — |
| Other cancers | 7.4% (35) | 6.3% (82) | — | — | 1.7% (5) |
| Hodgkin disease | 0.8% (4) | — | — | 1.1% (5) | 1.7% (5) |
| Gastric | 0.6% (3) | 0.3% (5) | 1.0% (27) | 5.4% (25) | 2.0% (6) |
| Type . | NY3 (N = 473), % (n) . | USIDNET23 (N = 1285), % (n) . | ESID2 (N = 2700), % (n) . | Italian21 (N = 455), % (n) . | Czech22 (N = 295), % (n) . |
|---|---|---|---|---|---|
| Any neoplasm | 14.4% (68) | 9.2% (119) | — | 29% (133) | 7.4% (25) |
| Non-Hodgkin lymphoma | 7.0% (33) | 2.2% (37) | 3.8% (103) | 7.2% (33) | 1.3% (4) |
| Solid tumors | — | — | 5.5% (149) | — | — |
| Other cancers | 7.4% (35) | 6.3% (82) | — | — | 1.7% (5) |
| Hodgkin disease | 0.8% (4) | — | — | 1.1% (5) | 1.7% (5) |
| Gastric | 0.6% (3) | 0.3% (5) | 1.0% (27) | 5.4% (25) | 2.0% (6) |